YOLFTbeta
NovaBridge Biosciences

NovaBridge Biosciences

NBP · NASDAQ · Healthcare / Biotechnology

0.8499USD+0.02 (+2.40%)

Price History

Full chart

Market Stats

Previous Close0.83
Open0.82
Day Range0.7801 – 0.8499
52-Week Range1.32 – 6.79
Volume776.11K
Market Cap159.59M
P/E (TTM)0.00
Forward P/E2.68
EPS-0.69
Dividend Yield0.00%
Beta1.50
50-Day Avg1.75
200-Day Avg2.54

About

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Srishti Gupta M.D.
  • Employees30
  • Headquarters2440 Research Boulevard, Rockville, MD, United States, 20850, USA
  • Websitehttps://novabridge.com

Leadership

  • Mr. Wei FuExecutive Chairman · b. 1982
  • Mr. Ming LeiChief Financial Officer · b. 1997
  • Mr. Sean Wuxiong Cao M.B.A., Ph.D.Chief Business Development Officer & Director · b. 1967
  • Dr. Srishti Gupta M.D.CEO & Director · b. 1976
  • Mr. Mark HaglerPresident & Chief Commercial Officer
  • Mr. Tyler EhlerSenior Director of Investor Relations
  • Ms. Liwei LinGeneral Counsel & Board Secretary · b. 1988
  • Dr. Cong Xu M.D., Ph.D.Senior VP and Head of R&D Center of Excellence · b. 1985
  • Dr. Phillip Dennis M.D., Ph.D.Chief Medical Officer · b. 1963

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue11.27M53.78M30.00M1.54B88.03M-10.70M4.49M00
Growth (%)-+377.40%-44.22%+5042.23%-94.29%-112.15%+141.93%-100.00%-
Cost of Revenue----46.43M27.24M0-858.26K
Gross Profit11.56M53.78M30.00M1.54B41.59M-10.70M4.49M--858.26K
Gross Margin102.58%100.00%100.00%100.00%47.25%100.00%100.00%--
Operating Expense285.44M509.53M1.49B1.39B2.11B355.38M515.65M-12.62M
Operating Income-273.89M-455.75M-1.46B155.57M-2.07B-366.08M-511.16M-375.36M-13.48M
Operating Margin-2431.25%-847.41%-4883.23%10.08%-2353.06%3422.17%-11395.09%--
EBITDA-279.32M-431.90M-197.26M168.31M-2.06B-356.38M-344.25M-373.45M-13.35M
EBITDA Margin-2479.47%-803.07%-657.53%10.91%-2337.41%3331.53%-7674.20%--
Net Income-298.24M-402.83M-1.45B470.92M-2.33B-967.52M-1.47B-162.26M-6.61M
Net Income Margin-2647.41%-749.02%-4826.77%30.53%-2648.70%9044.58%-32674.02%--
R&D267.07M426.03M840.41M984.69M190.29M155.51M114.36M158.90M8.99M
R&D as % of Total Revenue2370.77%792.15%2801.38%63.83%216.18%-1453.70%2549.35%--
Interest Expense864.34K1.70M427.48K146.48K01.30K101.85K--
Interest Expense % of Total Revenue7.67%3.16%1.42%0.01%0.00%-0.01%2.27%--

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.03B2.38B1.74B6.33B878.74M4.07B368.92M1.55B37.24M
Total Liabilities1.33B3.33B3.77B712.19M163.42M1.07B126.34M84.08M4.23M
Total Equity410.49M-955.10M1.07B5.63B715.33M3.01B242.58M1.47B33.02M
Cash307.93M1.59B1.14B4.76B552.80M3.21B291.51M498.24M30.11M
Total Debt213.01M147.03M132.50M19.14M17.64M38.29M3.89M28.33M438.46K
Net Debt-94.92M-1.44B-1.00B-4.74B-535.16M-3.18B-287.62M-469.90M-29.67M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-252.16M-280.70M-867.98M433.56M-973.09M-1.10B-72.85M-384.29M-20.60M
Investing Cash Flow-157.66M9.50M212.46M-201.90M-727.21M458.38M-107.63M-992.42M104.97M
Financing Cash Flow758.59M1.48B152.71M3.44B593.92M42.36M-8.25M-2.44M57.73M
Capital Expenditure20.33M14.41M12.24M8.01M29.93M45.83M164.35K350.34K7.00K
Free Cash Flow-272.48M-295.11M-880.22M425.55M-1.00B-1.15B-73.02M-384.77M-20.60M
Dividends Paid--5.28M------
FCF to OCF108.06%105.13%101.41%98.15%103.08%104.16%100.23%100.12%100.03%
Dividend Paid to FCF---0.60%------

Earnings

Report DateAug 31, 2020Dec 2, 2020Mar 29, 2021Apr 28, 2021Nov 11, 2021Apr 28, 2022Nov 9, 2022Aug 28, 2024Nov 14, 2024Dec 31, 2024May 15, 2025Aug 20, 2025Dec 18, 2025Dec 31, 2025Jun 25, 2026Sep 30, 2026
EPS Estimate-0.53--0.71-0.51-0.51-0.48-0.22-0.07-0.05-0.07-0.12-0.05-0.08-0.12-0.14
EPS Actual-0.800.032.190.56-0.86-0.70-0.550.30-0.11-0.06-0.04-0.07-0.06-0.31-0.04-0.07
Surprise-50.94%---21.13%-68.63%-37.25%-14.58%236.36%-57.14%-20.00%42.86%41.67%-20.00%-287.50%66.67%50.00%
TimingPre-market--Pre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-market---

Key Statistics & Ratios

Market Cap159.59M
Enterprise Value-26.31M
Trailing P/E0.00
Forward P/E2.68
Price / Sales25.39
Price / Book0.88
EPS-0.69
Book Value1.73
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-122.53M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-59.10%
Return on Assets-34.98%
Shares Outstanding115.65M
Shares Float64.45M
Beta1.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
34.41%
Insiders
14.16%
Retail / Other
51.43%

Top Institutional Holders

  • HHG PLC
    6.03M5.20%
  • Hillhouse Capital Advisors, Ltd.
    5.98M5.16%
  • Morgan Stanley - Brokerage Accounts
    3.84M3.31%
  • Siren, L.L.C.
    3.00M2.59%
  • AIHC Capital Management Limited
    2.88M2.48%
  • Point72 Asset Management, L.P.
    1.39M1.20%
  • Candriam Luxembourg S.C.A.
    1.13M0.98%
  • Adage Capital Partners Gp LLC
    1.00M0.86%
  • Two Sigma Investments LLC
    851.35K0.73%
  • Woodline Partners LP
    700.00K0.60%
  • BlackRock Inc
    627.50K0.54%
  • Citadel Advisors Llc
    622.83K0.54%
  • E Fund Management Co., Ltd.
    589.02K0.51%
  • Exome Asset Management LLC
    576.96K0.50%
  • State Street Corp
    370.11K0.32%
  • Fiera Capital Corporation
    315.68K0.27%

Top Fund Holders

  • Belfius Equities Cure C Cap
    1.13M0.98%
  • iShares Biotechnology ETF
    624.81K0.54%
  • E Fund Global Medi Inds Allc QDII CNY A
    589.02K0.51%
  • OAKS Emerg and Frntr Opp A EUR Acc Ser 4
    315.68K0.27%